Laboratory Co. of America (LH) Financials

$242.69 +0.80 (+0.33%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$246.50 +3.81 (+1.57%)

As of 05/23/2025 07:57 PM Eastern

Annual Income Statements for Laboratory Co. of America

This table shows Laboratory Co. of America's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	746	418	1,279	2,377	1,556	824	884	1,227	712	438
Consolidated Net Income / (Loss)	747	419	1,281	2,380	1,557	825	884	1,233	713	439
Net Income / (Loss) Continuing Operations	747	380	1,004	2,198	1,557	825	884	1,233	713	439
Total Pre-Tax Income	960	569	1,237	2,888	2,219	1,105	1,268	1,078	1,074	726
Total Operating Income	1,087	726	1,437	3,049	2,445	1,330	1,326	1,305	1,271	997
Total Gross Profit	3,624	3,365	3,709	4,992	4,953	3,253	3,176	3,092	2,854	2,903
Total Revenue	13,009	12,162	11,864	13,136	13,979	11,555	11,333	10,308	9,553	8,680
Operating Revenue	13,009	12,162	11,864	13,136	13,979	11,555	11,333	10,308	9,553	8,680
Total Cost of Revenue	9,385	8,797	8,155	8,144	9,026	8,302	8,157	7,216	6,699	5,777
Operating Cost of Revenue	9,385	8,797	8,155	8,144	9,026	8,302	8,157	7,216	6,699	5,777
Total Operating Expenses	2,538	2,639	2,272	1,944	2,507	1,922	1,851	1,787	1,583	1,907
Selling, General & Admin Expense	2,230	2,021	1,763	1,690	1,729	1,625	1,571	1,499	1,346	1,628
Amortization Expense	256	220	194	230	275	243	232	217	180	165
Impairment Charge	5.30	349	262	0.00	462	-	0.00	-	-	-
Restructuring Charge	46	49	54	24	41	55	48	71	58	114
Total Other Income / (Expense), net	-127	-157	-199	-161	-226	-225	-57	-228	-197	-271
Interest Expense	208	200	180	212	207	241	244	235	219	275
Interest & Investment Income	21	27	13	35	13	19	19	13	9.60	12
Other Income / (Expense), net	60	16	-32	16	-32	-3.20	168	-6.00	13	-7.80
Income Tax Expense	212	189	234	690	662	280	384	-155	361	287
Net Income / (Loss) Discontinued Operations	0.00	39	277	182	-	-	-	-	-	-
Net Income / (Loss) Attributable to Noncontrolling Interest	1.10	1.20	1.50	2.20	0.90	1.10	0.20	5.80	1.10	1.10
Basic Earnings per Share	$8.89	$4.80	$14.05	$24.60	-	-	-	-	-	-
Weighted Average Basic Shares Outstanding	83.70M	84.10M	88.50M	93.40M	195.20M	97.30M	101.40M	102.40M	102.50M	98.80M
Diluted Earnings per Share	$8.84	$4.77	$13.97	$24.39	-	-	-	-	-	-
Weighted Average Diluted Shares Outstanding	83.70M	84.10M	88.50M	93.40M	195.20M	97.30M	101.40M	102.40M	102.50M	98.80M
Weighted Average Basic & Diluted Shares Outstanding	83.70M	84.10M	88.50M	93.40M	195.20M	97.30M	101.40M	102.40M	102.50M	98.80M
Cash Dividends to Common per Share	$2.88	$2.88	$2.16	-	-	-	-	-	-	-

This table shows Laboratory Co. of America's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	213	143	169	205	228	-167	183	189	213	76	353
Consolidated Net Income / (Loss)	213	144	170	206	228	-167	184	189	213	76	353
Net Income / (Loss) Continuing Operations	213	144	170	206	228	-167	184	155	208	-34	277
Total Pre-Tax Income	275	184	211	268	297	-147	239	205	272	-78	316
Total Operating Income	326	217	254	295	321	-123	252	266	330	-54	374
Total Gross Profit	948	896	904	926	897	821	851	842	850	647	886
Total Revenue	3,345	3,329	3,282	3,221	3,177	3,033	3,057	3,034	3,038	2,175	2,867
Operating Revenue	3,345	3,329	3,282	3,221	3,177	3,033	3,057	3,034	3,038	2,175	2,867
Total Cost of Revenue	2,397	2,433	2,378	2,295	2,279	2,212	2,206	2,192	2,188	1,527	1,981
Operating Cost of Revenue	2,397	2,433	2,378	2,295	2,279	2,212	2,206	2,192	2,188	1,527	1,981
Total Operating Expenses	622	680	650	632	576	944	599	576	520	702	512
Selling, General & Admin Expense	546	595	569	558	508	533	526	506	457	413	453
Amortization Expense	70	70	64	62	60	59	56	52	53	28	49
Impairment Charge	0.00	2.80	0.00	0.00	2.50	334	10	2.80	2.20	261	0.00
Restructuring Charge	6.40	11	18	12	5.00	18	7.50	16	7.50	-0.10	10
Total Other Income / (Expense), net	-51	-33	-44	-27	-24	-24	-14	-61	-58	-24	-59
Interest Expense	56	63	50	48	47	49	50	50	51	49	46
Interest & Investment Income	6.20	14	2.60	1.00	3.00	6.30	16	5.40	0.10	-0.10	5.40
Other Income / (Expense), net	-1.00	16	4.30	20	20	18	21	-17	-6.90	25	-18
Income Tax Expense	62	40	41	62	69	20	55	50	64	-44	38
Net Income / (Loss) Attributable to Noncontrolling Interest	0.20	0.20	0.30	0.30	0.30	0.30	0.30	0.20	0.40	0.30	0.40
Basic Earnings per Share	$2.54	$1.72	$2.02	$2.44	$2.71	($1.86)	$2.12	$2.13	$2.41	$0.98	$3.91
Weighted Average Basic Shares Outstanding	83.70M	83.70M	83.64M	83.96M	84.29M	84.10M	84.90M	-	88.60M	88.50M	88.60M
Diluted Earnings per Share	$2.52	$1.72	$2.00	$2.43	$2.69	($1.85)	$2.11	$2.12	$2.39	$0.97	$3.90
Weighted Average Diluted Shares Outstanding	83.70M	83.70M	83.64M	83.96M	84.29M	84.10M	84.90M	-	88.60M	88.50M	88.60M
Weighted Average Basic & Diluted Shares Outstanding	83.70M	83.70M	83.64M	83.96M	84.29M	84.10M	84.90M	-	88.60M	88.50M	88.60M
Cash Dividends to Common per Share	$0.72	-	-	-	-	-	-	-	-	-	-

This table details how cash moves in and out of Laboratory Co. of America's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	982	158	-555	152	983	-89	480	-117	-283	136
Net Cash From Operating Activities	1,586	1,328	1,956	3,110	2,135	1,445	1,305	1,498	1,197	982
Net Cash From Continuing Operating Activities	1,586	1,202	1,765	2,846	2,135	1,445	1,675	1,498	1,197	982
Net Income / (Loss) Continuing Operations	747	380	1,004	2,198	1,557	825	884	1,233	713	439
Consolidated Net Income / (Loss)	747	419	1,281	2,380	1,557	825	884	1,233	713	439
Net Income / (Loss) Discontinued Operations	0.00	39	277	182	-	-	-	-	-	-
Depreciation Expense	644	577	537	741	825	771	552	533	499	458
Non-Cash Adjustments To Reconcile Net Income	152	674	528	92	531	61	196	110	103	149
Changes in Operating Assets and Liabilities, net	-34	-378	185	-184	-778	-213	44	-378	-118	-63
Net Cash From Discontinued Operating Activities	0.00	125	191	263	-	-	-	-	-	-
Net Cash From Investing Activities	-1,367	-1,172	-1,652	-885	-643	-1,283	207	-2,229	-796	-3,995
Net Cash From Continuing Investing Activities	-1,367	-1,147	-1,600	-846	-643	-1,283	207	-2,229	-796	-3,995
Purchase of Property, Plant & Equipment	-490	-454	-429	-422	-382	-400	-380	-313	-279	-256
Acquisitions	-894	-701	-1,181	-525	-308	-904	-140	-1,921	-561	-3,748
Sale of Property, Plant & Equipment	2.00	0.60	1.40	87	42	7.70	50	5.50	31	0.60
Divestitures	15	0.00	1.60	0.00	3.10	0.00	658	0.00	14	8.00
Sale and/or Maturity of Investments	0.00	6.70	8.10	13	1.00	13	18	0.00	0.00	-
Net Cash From Discontinued Investing Activities	0.00	-25	-53	-39	-	-	-	-	-	-
Net Cash From Financing Activities	780	-59	-1,322	-2,066	-517	-253	-1,390	593	-671	3,185
Net Cash From Continuing Financing Activities	780	-1,559	-1,322	-2,066	-517	-253	-1,390	593	-671	3,185
Repayment of Debt	-3,500	-2,808	-814	-1,402	-591	-1,727	-1,162	-2,401	-643	-602
Repurchase of Common Equity	-250	-1,000	-1,100	-1,669	-100	-450	-700	-338	-44	0.00
Payment of Dividends	-243	-254	-195	-	-	-	-	-	-2.10	0.00
Issuance of Debt	4,764	2,488	787	1,000	117	1,900	467	3,342	140	3,960
Issuance of Common Equity	56	54	51	4.20	56	65	69	74	71	99
Other Financing Activities, net	-46	-40	-51	-	-	-41	-64	-84	-192	-272
Net Cash From Discontinued Financing Activities	0.00	1,500	0.00	0.00	-	-	-	-	-	-
Other Net Changes in Cash	-17	-	-	-	-	-	-	-	-	-

This table details how cash moves in and out of Laboratory Co. of America's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-1,149	1.40	1,252	166	-438	-140	-1,312	1,646	-36	508	-659
Net Cash From Operating Activities	19	777	277	561	-30	580	276	351	121	654	374
Net Cash From Continuing Operating Activities	19	777	277	561	-30	580	276	162	186	607	253
Net Income / (Loss) Continuing Operations	213	144	170	206	228	-167	184	155	208	37	277
Consolidated Net Income / (Loss)	213	144	170	206	228	-167	184	189	213	76	353
Depreciation Expense	215	34	210	201	199	18	189	188	183	1.40	176
Non-Cash Adjustments To Reconcile Net Income	31	119	7.50	11	15	576	10	26	62	478	8.60
Changes in Operating Assets and Liabilities, net	-441	404	-109	143	-471	205	-108	-207	-268	579	-208
Net Cash From Investing Activities	-336	-210	-579	-185	-393	-331	-488	-254	-100	-273	-563
Net Cash From Continuing Investing Activities	-336	-210	-579	-185	-393	-331	-488	-245	-84	-255	-543
Purchase of Property, Plant & Equipment	-126	-112	-116	-128	-134	-167	-105	-103	-78	-99	-83
Acquisitions	-211	-101	-464	-57	-273	-164	-390	-141	-5.90	-162	-460
Sale of Property, Plant & Equipment	0.50	1.40	0.40	0.10	0.10	0.30	0.10	0.10	0.10	0.20	0.10
Divestitures	0.00	1.60	-	-	14	-6.70	6.70	-	0.00	0.90	0.30
Net Cash From Financing Activities	-840	-547	1,548	-210	-12	-447	-1,097	1,545	-61	-373	-452
Net Cash From Continuing Financing Activities	-840	-547	1,548	-210	-12	-447	-988	-64	-61	-373	-452
Repayment of Debt	-1,068	-437	-2,132	-721	-211	-929	-458	-593	-828	-814	-
Payment of Dividends	-62	-60	-61	-60	-62	-61	-64	-65	-64	-64	-65
Issuance of Debt	290	-	3,812	699	253	520	548	593	828	787	-
Issuance of Common Equity	26	3.20	26	-	27	-	-	27	28	-	32
Other Financing Activities, net	-26	22	-23	-27	-19	15	-4.50	-26	-24	18	-19
Effect of Exchange Rate Changes	7.90	-	5.70	-0.30	-2.90	6.40	-2.80	3.30	3.00	12	-17

This table presents Laboratory Co. of America's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	18,379	16,725	20,155	20,385	20,072	18,046	16,185	16,673	14,247	14,105
Total Current Assets	4,807	3,765	4,625	5,331	5,125	2,981	2,835	2,734	2,479	2,621
Cash & Equivalents	1,519	537	321	1,473	1,321	338	427	317	434	716
Accounts Receivable	2,097	2,099	1,997	2,978	3,017	2,025	1,862	1,848	1,519	1,375
Inventories, net	493	475	471	401	423	245	237	227	205	191
Prepaid Expenses	698	655	610	478	365	374	309	309	321	339
Plant, Property, & Equipment, net	3,045	2,912	2,794	2,815	2,730	2,637	1,740	1,707	1,719	1,747
Total Noncurrent Assets	10,527	10,048	12,736	12,240	12,217	12,429	11,610	11,843	10,048	9,734
Long-Term Investments	16	27	66	61	74	85	61	58	58	58
Goodwill	6,370	6,143	6,124	7,959	7,752	7,865	7,360	7,401	6,424	6,202
Intangible Assets	3,489	3,342	3,124	3,736	3,961	4,035	3,911	4,166	3,401	3,324
Other Noncurrent Operating Assets	652	537	378	463	410	435	276	218	165	150
Total Liabilities & Shareholders' Equity	18,379	16,725	20,155	20,385	20,072	18,046	16,185	16,673	14,247	14,105
Total Liabilities	10,313	8,835	10,059	10,091	10,614	10,459	9,195	9,762	8,726	9,145
Total Current Liabilities	3,330	3,225	3,079	2,783	3,079	2,656	1,879	2,166	1,828	1,701
Short-Term Debt	1,000	1,000	301	1.50	377	415	10	418	550	424
Accounts Payable	876	828	852	621	639	632	635	574	508	497
Accrued Expenses	871	804	787	1,404	1,358	942	870	793	594	633
Current Deferred Revenue	392	422	311	559	507	451	356	381	176	146
Other Current Liabilities	191	172	170	198	199	215	7.90	-	-	-
Total Noncurrent Liabilities	6,982	5,609	6,980	7,309	7,536	7,804	7,316	7,596	6,898	7,444
Long-Term Debt	5,331	4,055	5,039	5,417	5,419	5,790	5,991	6,345	5,300	5,940
Capital Lease Obligations	74	79	-	-	-	-	51	-	-	-
Noncurrent Deferred & Payable Income Tax Liabilities	383	418	543	763	829	943	940	876	1,206	1,181
Other Noncurrent Operating Liabilities	1,194	1,058	1,157	1,129	1,288	1,071	334	376	392	323
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Redeemable Noncontrolling Interest	14	16	-	21	21	20	-	-	-	-
Total Equity & Noncontrolling Interests	8,052	7,875	10,097	10,273	9,437	7,567	6,991	6,825	5,521	4,960
Total Preferred & Common Equity	8,052	7,875	10,097	10,273	9,437	7,567	6,971	6,825	5,521	4,960
Total Common Equity	8,052	7,875	10,097	10,273	9,437	7,567	6,971	6,825	5,521	4,960
Common Stock	10	46	8.10	8.50	119	36	1,463	2,023	2,159	2,001
Retained Earnings	8,303	7,888	10,582	10,457	9,479	7,904	7,080	6,196	4,956	4,224
Accumulated Other Comprehensive Income / (Loss)	-262	-59	-493	-192	-162	-372	-463	-334	-581	-287

This table presents Laboratory Co. of America's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	12/31/2022	9/30/2022
Total Assets	17,604	18,379	18,613	16,712	16,531	16,725	16,886	17,719	20,155	19,826
Total Current Assets	3,790	4,807	4,910	3,571	3,457	3,765	3,954	5,121	4,625	4,372
Cash & Equivalents	369	1,519	1,517	265	99	537	728	1,931	321	410
Accounts Receivable	2,275	2,097	2,225	2,246	2,204	2,099	2,065	2,043	1,997	2,983
Inventories, net	488	493	483	442	475	475	461	488	471	468
Prepaid Expenses	658	698	685	618	678	655	700	660	610	512
Plant, Property, & Equipment, net	3,091	3,045	3,050	2,933	2,898	2,912	2,821	2,762	2,794	2,885
Total Noncurrent Assets	10,723	10,527	10,653	10,209	10,177	10,048	10,111	9,836	12,736	12,570
Long-Term Investments	168	16	17	18	18	27	40	67	66	64
Goodwill	6,421	6,370	6,482	6,220	6,219	6,143	6,332	6,182	6,124	8,218
Intangible Assets	3,487	3,489	3,541	3,332	3,394	3,342	3,276	3,154	3,124	3,808
Other Noncurrent Operating Assets	647	652	613	639	546	537	457	426	378	451
Total Liabilities & Shareholders' Equity	17,604	18,379	18,613	16,712	16,531	16,725	16,886	17,719	20,155	19,826
Total Liabilities	9,282	10,313	10,427	8,692	8,556	8,835	8,994	8,914	10,059	9,715
Total Current Liabilities	2,065	3,330	3,412	4,065	3,942	3,225	2,901	2,183	3,079	2,522
Short-Term Debt	0.40	1,000	1,400	2,020	2,042	1,000	991	301	301	-
Accounts Payable	718	876	661	761	696	828	691	713	852	766
Accrued Expenses	770	871	758	708	649	804	690	658	787	1,041
Current Deferred Revenue	388	392	403	388	378	422	361	350	311	531
Other Current Liabilities	188	191	191	189	178	172	169	161	170	185
Total Noncurrent Liabilities	7,218	6,982	7,030	4,642	4,630	5,609	6,112	6,750	6,980	7,212
Long-Term Debt	5,569	5,331	5,352	3,047	3,048	4,055	4,428	5,042	5,039	5,334
Capital Lease Obligations	67	74	-	-	-	79	-	-	-	-
Noncurrent Deferred & Payable Income Tax Liabilities	388	383	358	376	397	418	500	565	543	673
Other Noncurrent Operating Liabilities	1,194	1,194	1,320	1,218	1,185	1,058	1,185	1,144	1,157	1,205
Redeemable Noncontrolling Interest	14	14	-	-	-	16	-	-	-	-
Total Equity & Noncontrolling Interests	8,307	8,052	8,170	8,006	7,960	7,875	7,873	8,785	10,097	10,092
Total Preferred & Common Equity	8,307	8,052	8,170	8,006	7,960	7,875	7,873	8,785	10,097	10,092
Total Common Equity	8,307	8,052	8,170	8,006	7,960	7,875	7,873	8,785	10,097	10,092
Common Stock	43	10	7.60	20	90	46	12	103	8.10	8.20
Retained Earnings	8,456	8,303	8,276	8,178	8,055	7,888	8,070	8,836	10,582	10,845
Accumulated Other Comprehensive Income / (Loss)	-192	-262	-113	-192	-185	-59	-209	-154	-493	-761

This table displays calculated financial ratios and metrics derived from Laboratory Co. of America's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	6.97%	2.51%	-9.68%	-6.03%	20.98%	1.95%	9.95%	7.90%	10.06%	44.39%
EBITDA Growth	35.80%	-32.09%	-48.98%	17.50%	54.33%	2.58%	11.63%	2.81%	23.19%	24.05%
EBIT Growth	54.76%	-47.23%	-54.17%	26.97%	81.86%	-11.14%	14.95%	1.25%	29.74%	7.41%
NOPAT Growth	74.40%	-58.35%	-49.79%	35.22%	72.77%	7.49%	-38.14%	77.01%	40.07%	6.70%
Net Income Growth	78.22%	-67.27%	-46.18%	52.83%	88.75%	-6.68%	-28.31%	72.94%	62.50%	-14.42%
EPS Growth	85.32%	-65.86%	-42.72%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	19.44%	-32.12%	-37.10%	45.63%	47.80%	10.67%	-12.86%	25.14%	21.85%	32.94%
Free Cash Flow Firm Growth	227.27%	-107.92%	82.88%	63.06%	587.25%	-85.65%	346.58%	-198.18%	110.83%	-1,309.92%
Invested Capital Growth	3.83%	6.63%	-17.59%	2.31%	3.66%	6.49%	-2.49%	18.37%	3.13%	102.80%
Revenue Q/Q Growth	2.33%	7.60%	10.25%	-20.65%	12.35%	1.46%	0.38%	4.09%	0.41%	9.98%
EBITDA Q/Q Growth	24.60%	-4.28%	-22.08%	-20.73%	42.29%	7.74%	-3.45%	2.88%	4.56%	5.00%
EBIT Q/Q Growth	41.70%	-9.23%	-26.75%	-20.70%	63.22%	6.65%	-4.21%	2.90%	5.41%	1.45%
NOPAT Q/Q Growth	62.96%	-24.10%	-27.51%	-19.12%	72.98%	3.63%	-36.13%	77.57%	5.28%	0.84%
Net Income Q/Q Growth	71.08%	-36.72%	-27.15%	-13.93%	84.11%	9.13%	-37.57%	74.38%	8.21%	-2.16%
EPS Q/Q Growth	67.74%	-37.15%	-25.53%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	14.23%	-5.28%	-2.20%	-2.42%	10.61%	6.13%	-5.68%	6.76%	7.69%	21.06%
Free Cash Flow Firm Q/Q Growth	207.05%	-109.44%	635.63%	-13.80%	13.10%	-45.98%	-21.45%	49.01%	-71.83%	18.37%
Invested Capital Q/Q Growth	-3.37%	-0.51%	-21.85%	2.42%	4.24%	-0.14%	-1.61%	-0.17%	-1.71%	-12.76%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	27.86%	27.67%	31.26%	38.01%	35.43%	28.15%	28.03%	29.99%	29.88%	33.45%
EBITDA Margin	13.76%	10.84%	16.36%	28.97%	23.17%	18.16%	18.05%	17.78%	18.66%	16.67%
Operating Margin	8.35%	5.97%	12.11%	23.21%	17.49%	11.51%	11.70%	12.66%	13.30%	11.48%
EBIT Margin	8.82%	6.09%	11.84%	23.33%	17.26%	11.48%	13.18%	12.60%	13.43%	11.39%
Profit (Net Income) Margin	5.74%	3.45%	10.79%	18.11%	11.14%	7.14%	7.80%	11.96%	7.46%	5.05%
Tax Burden Percent	77.86%	73.69%	103.49%	82.40%	70.16%	74.66%	69.69%	114.42%	66.40%	60.43%
Interest Burden Percent	83.66%	76.76%	88.12%	94.24%	91.95%	83.26%	84.93%	82.94%	83.67%	73.41%
Effective Tax Rate	22.14%	33.13%	18.90%	23.90%	29.84%	25.34%	30.31%	-14.42%	33.60%	39.57%
Return on Invested Capital (ROIC)	6.66%	4.02%	9.01%	16.55%	12.60%	7.66%	7.27%	12.58%	7.88%	7.65%
ROIC Less NNEP Spread (ROIC-NNEP)	4.57%	1.88%	13.23%	17.98%	9.48%	4.70%	6.58%	8.01%	5.49%	3.53%
Return on Net Nonoperating Assets (RNNOA)	2.70%	0.64%	3.55%	7.54%	5.67%	3.66%	5.53%	7.40%	5.73%	3.60%
Return on Equity (ROE)	9.36%	4.66%	12.56%	24.09%	18.27%	11.32%	12.80%	19.97%	13.60%	11.25%
Cash Return on Invested Capital (CROIC)	2.90%	-2.40%	28.29%	14.27%	9.01%	1.38%	9.78%	-4.25%	4.80%	-60.25%
Operating Return on Assets (OROA)	6.53%	4.02%	6.93%	15.15%	12.66%	7.75%	9.09%	8.40%	9.05%	9.24%
Return on Assets (ROA)	4.26%	2.27%	6.32%	11.76%	8.17%	4.82%	5.38%	7.97%	5.03%	4.10%
Return on Common Equity (ROCE)	9.35%	4.66%	12.55%	24.04%	18.23%	11.29%	12.78%	19.97%	13.60%	11.25%
Return on Equity Simple (ROE_SIMPLE)	9.28%	5.32%	12.68%	23.16%	16.50%	10.90%	12.68%	18.06%	12.91%	8.84%
Net Operating Profit after Tax (NOPAT)	846	485	1,165	2,320	1,716	993	924	1,493	844	602
NOPAT Margin	6.50%	3.99%	9.82%	17.66%	12.27%	8.59%	8.15%	14.49%	8.83%	6.94%
Net Nonoperating Expense Percent (NNEP)	2.10%	2.14%	-4.23%	-1.43%	3.12%	2.96%	0.69%	4.57%	2.39%	4.12%
Return On Investment Capital (ROIC_SIMPLE)	5.85%	3.73%	7.55%	14.79%	11.26%	7.21%	7.08%	10.99%	7.42%	5.32%
Cost of Revenue to Revenue	72.14%	72.33%	68.74%	61.99%	64.57%	71.85%	71.97%	70.01%	70.12%	66.55%
SG&A Expenses to Revenue	17.14%	16.62%	14.86%	12.87%	12.37%	14.06%	13.86%	14.54%	14.08%	18.76%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	19.51%	21.70%	19.15%	14.80%	17.94%	16.64%	16.33%	17.33%	16.58%	21.96%
Earnings before Interest and Taxes (EBIT)	1,147	741	1,404	3,064	2,413	1,327	1,493	1,299	1,283	989
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,790	1,318	1,942	3,805	3,238	2,098	2,046	1,832	1,782	1,447
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.51	2.52	2.04	2.89	2.07	2.14	1.81	2.35	2.37	2.49
Price to Tangible Book Value (P/TBV)	0.00	0.00	24.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.56	1.63	1.74	2.26	1.40	1.40	1.11	1.56	1.37	1.42
Price to Earnings (P/E)	27.13	47.52	16.11	12.49	12.58	19.69	14.25	13.07	18.34	28.23
Dividend Yield	0.94%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.69%	2.10%	6.21%	8.01%	7.95%	5.08%	7.02%	7.65%	5.45%	3.54%
Enterprise Value to Invested Capital (EV/IC)	1.94	1.96	2.19	2.37	1.73	1.65	1.45	1.74	1.69	1.70
Enterprise Value to Revenue (EV/Rev)	1.93	2.01	2.15	2.56	1.72	1.91	1.60	2.18	1.93	2.07
Enterprise Value to EBITDA (EV/EBITDA)	14.03	18.54	13.16	8.83	7.41	10.50	8.88	12.24	10.33	12.40
Enterprise Value to EBIT (EV/EBIT)	21.90	32.99	18.20	10.96	9.94	16.60	12.17	17.26	14.35	18.14
Enterprise Value to NOPAT (EV/NOPAT)	29.69	50.39	21.94	14.48	13.99	22.18	19.67	15.01	21.83	29.79
Enterprise Value to Operating Cash Flow (EV/OCF)	15.84	18.41	13.07	10.80	11.24	15.24	13.92	14.97	15.38	18.27
Enterprise Value to Free Cash Flow (EV/FCFF)	68.13	0.00	6.99	16.80	19.56	123.37	14.61	0.00	35.84	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.79	0.65	0.53	0.53	0.61	0.82	0.87	0.99	1.06	1.28
Long-Term Debt to Equity	0.67	0.52	0.50	0.53	0.57	0.76	0.86	0.93	0.96	1.20
Financial Leverage	0.59	0.34	0.27	0.42	0.60	0.78	0.84	0.92	1.04	1.02
Leverage Ratio	2.20	2.05	1.99	2.05	2.24	2.35	2.38	2.50	2.71	2.75
Compound Leverage Factor	1.84	1.57	1.75	1.93	2.06	1.96	2.02	2.08	2.26	2.02
Debt to Total Capital	44.26%	39.41%	34.59%	34.48%	38.00%	44.99%	46.40%	49.77%	51.44%	56.20%
Short-Term Debt to Total Capital	6.91%	7.68%	1.95%	0.01%	2.47%	3.01%	0.08%	3.07%	4.83%	3.74%
Long-Term Debt to Total Capital	37.35%	31.74%	32.64%	34.47%	35.53%	41.98%	46.33%	46.70%	46.61%	52.46%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.10%	0.12%	0.00%	0.13%	0.14%	0.15%	0.15%	0.00%	0.00%	0.00%
Common Equity to Total Capital	55.64%	60.47%	65.41%	65.39%	61.87%	54.86%	53.45%	50.23%	48.56%	43.80%
Debt to EBITDA	3.58	3.89	2.75	1.42	1.79	2.96	2.96	3.69	3.28	4.40
Net Debt to EBITDA	2.72	3.47	2.55	1.02	1.36	2.76	2.72	3.49	3.01	3.86
Long-Term Debt to EBITDA	3.02	3.14	2.60	1.42	1.67	2.76	2.95	3.46	2.97	4.11
Debt to NOPAT	7.57	10.58	4.58	2.34	3.38	6.25	6.55	4.53	6.93	10.57
Net Debt to NOPAT	5.76	9.42	4.25	1.67	2.57	5.82	6.02	4.28	6.35	9.28
Long-Term Debt to NOPAT	6.39	8.52	4.33	2.33	3.16	5.83	6.54	4.25	6.28	9.86
Altman Z-Score	2.82	2.92	2.87	3.77	2.98	2.45	2.51	2.42	2.41	2.16
Noncontrolling Interest Sharing Ratio	0.19%	0.09%	0.10%	0.21%	0.24%	0.27%	0.14%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.44	1.17	1.50	1.92	1.66	1.12	1.51	1.26	1.36	1.54
Quick Ratio	1.09	0.82	0.75	1.60	1.41	0.89	1.22	1.00	1.07	1.23
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	369	-290	3,658	2,000	1,227	179	1,244	-504	514	-4,744
Operating Cash Flow to CapEx	325.03%	293.09%	457.09%	930.46%	628.77%	368.08%	395.94%	487.35%	482.51%	384.95%
Free Cash Flow to Firm to Interest Expense	1.77	-1.45	20.35	9.44	5.92	0.74	5.09	-2.15	2.35	-17.26
Operating Cash Flow to Interest Expense	7.61	6.65	10.88	14.68	10.30	6.00	5.35	6.37	5.46	3.57
Operating Cash Flow Less CapEx to Interest Expense	5.27	4.38	8.50	13.10	8.66	4.37	4.00	5.06	4.33	2.65
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.74	0.66	0.59	0.65	0.73	0.68	0.69	0.67	0.67	0.81
Accounts Receivable Turnover	6.20	5.94	4.77	4.38	5.54	5.94	6.11	6.12	6.60	7.93
Inventory Turnover	19.39	18.61	18.70	19.75	27.03	34.45	35.12	33.38	33.82	34.96
Fixed Asset Turnover	4.37	4.26	4.23	4.74	5.21	5.28	6.58	6.02	5.51	6.85
Accounts Payable Turnover	11.02	10.47	11.07	12.92	14.20	13.11	13.50	13.33	13.32	14.82
Days Sales Outstanding (DSO)	58.86	61.47	76.54	83.29	65.83	61.40	59.74	59.60	55.27	46.05
Days Inventory Outstanding (DIO)	18.82	19.61	19.51	18.48	13.51	10.60	10.39	10.94	10.79	10.44
Days Payable Outstanding (DPO)	33.12	34.85	32.98	28.24	25.70	27.85	27.04	27.37	27.40	24.63
Cash Conversion Cycle (CCC)	44.56	46.23	63.08	73.53	53.63	44.15	43.09	43.16	38.66	31.86
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	12,937	12,460	11,685	14,178	13,859	13,370	12,555	12,875	10,877	10,547
Invested Capital Turnover	1.02	1.01	0.92	0.94	1.03	0.89	0.89	0.87	0.89	1.10
Increase / (Decrease) in Invested Capital	477	775	-2,493	320	489	815	-320	1,998	330	5,346
Enterprise Value (EV)	25,122	24,448	25,555	33,597	23,999	22,023	18,173	22,421	18,415	17,945
Market Capitalization	20,237	19,863	20,602	29,692	19,577	16,220	12,590	16,034	13,057	12,355
Book Value per Share	$96.27	$92.76	$113.96	$107.35	$96.89	$77.93	$69.09	$67.04	$53.60	$49.01
Tangible Book Value per Share	($21.60)	($18.96)	$9.59	($14.85)	($23.37)	($44.62)	($42.62)	($46.58)	($41.79)	($45.11)
Total Capital	14,472	13,024	15,437	15,712	15,253	13,792	13,042	13,587	11,371	11,324
Total Debt	6,406	5,133	5,340	5,418	5,796	6,205	6,052	6,762	5,850	6,364
Total Long-Term Debt	5,406	4,133	5,039	5,417	5,419	5,790	6,042	6,345	5,300	5,940
Net Debt	4,871	4,569	4,954	3,884	4,401	5,783	5,565	6,387	5,358	5,590
Capital Expenditures (CapEx)	488	453	428	334	340	393	330	307	248	255
Debt-free, Cash-free Net Working Capital (DFCFNWC)	958	1,003	1,527	1,076	1,103	403	540	669	767	628
Debt-free Net Working Capital (DFNWC)	2,477	1,540	1,848	2,549	2,424	741	967	986	1,201	1,345
Net Working Capital (NWC)	1,476	540	1,547	2,548	2,047	325	957	568	651	921
Net Nonoperating Expense (NNE)	99	66	-116	-59	159	168	40	261	131	164
Net Nonoperating Obligations (NNO)	4,871	4,569	1,588	3,884	4,401	5,783	5,565	6,050	5,356	5,587
Total Depreciation and Amortization (D&A)	644	577	537	741	825	771	552	533	499	458
Debt-free, Cash-free Net Working Capital to Revenue	7.36%	8.25%	12.87%	8.19%	7.89%	3.49%	4.76%	6.49%	8.03%	7.24%
Debt-free Net Working Capital to Revenue	19.04%	12.66%	15.58%	19.41%	17.34%	6.41%	8.53%	9.56%	12.57%	15.49%
Net Working Capital to Revenue	11.35%	4.44%	13.04%	19.39%	14.64%	2.82%	8.44%	5.51%	6.82%	10.61%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$8.89	$4.80	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	83.70M	84.10M	88.50M	0.00	97.60M	97.30M	98.60M	101.90M	102.30M	0.00
Adjusted Diluted Earnings per Share	$8.84	$4.77	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	83.70M	84.10M	88.50M	0.00	97.60M	97.30M	98.60M	101.90M	102.30M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	83.70M	84.10M	88.50M	0.00	97.60M	97.30M	98.60M	101.90M	102.30M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	886	751	1,421	2,338	2,068	1,034	957	963	882	671
Normalized NOPAT Margin	6.81%	6.18%	11.98%	17.80%	14.80%	8.95%	8.45%	9.34%	9.24%	7.73%
Pre Tax Income Margin	7.38%	4.68%	10.43%	21.98%	15.88%	9.56%	11.19%	10.45%	11.24%	8.36%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	5.51	3.71	7.81	14.47	11.64	5.51	6.12	5.53	5.86	3.60
NOPAT to Interest Expense	4.06	2.43	6.48	10.95	8.27	4.13	3.78	6.35	3.85	2.19
EBIT Less CapEx to Interest Expense	3.16	1.44	5.43	12.89	10.00	3.88	4.77	4.22	4.72	2.67
NOPAT Less CapEx to Interest Expense	1.72	0.16	4.10	9.38	6.64	2.50	2.43	5.04	2.72	1.26
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	32.54%	60.59%	15.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.29%	0.00%
Augmented Payout Ratio	66.02%	299.14%	101.14%	70.12%	6.42%	54.55%	79.19%	27.42%	6.45%	0.00%

This table displays calculated financial ratios and metrics derived from Laboratory Co. of America's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	5.30%	9.76%	7.37%	6.17%	4.57%	39.49%	6.63%	3.79%	-22.10%	102.98%	-29.43%
EBITDA Growth	0.09%	407.73%	1.15%	18.04%	6.81%	-211.87%	-13.01%	-20.45%	-43.09%	-105.32%	-48.55%
EBIT Growth	-4.78%	322.66%	-5.49%	26.02%	5.70%	-258.22%	-23.29%	-37.54%	-52.36%	-106.04%	-55.38%
NOPAT Growth	2.30%	296.78%	5.45%	12.30%	-2.28%	-126.57%	-40.96%	-36.83%	-52.27%	-108.78%	-43.98%
Net Income Growth	-6.70%	186.09%	-7.63%	8.73%	7.03%	-318.32%	-48.02%	-47.31%	-56.66%	-86.20%	-39.91%
EPS Growth	-6.32%	192.97%	-5.21%	14.62%	12.55%	-290.72%	-45.90%	-45.22%	-54.30%	-83.16%	-35.54%
Operating Cash Flow Growth	162.08%	34.09%	0.65%	59.68%	-124.59%	-11.32%	-26.30%	-38.62%	-65.96%	-6.29%	-51.28%
Free Cash Flow Firm Growth	57.43%	64.19%	-125.13%	-184.68%	95.34%	-135.06%	435.77%	2,240.94%	-184.74%	2,083.54%	-2,112.83%
Invested Capital Growth	3.78%	3.83%	6.90%	0.00%	6.60%	6.63%	-16.24%	0.00%	0.00%	-17.59%	8.02%
Revenue Q/Q Growth	0.47%	1.44%	1.90%	1.39%	4.72%	-0.77%	0.76%	-0.14%	39.70%	-24.15%	-1.92%
EBITDA Q/Q Growth	102.55%	-42.99%	-9.25%	-4.48%	722.72%	-118.74%	5.91%	-13.57%	1,918.35%	-105.23%	-3.15%
EBIT Q/Q Growth	39.54%	-9.87%	-17.79%	-7.91%	426.29%	-138.26%	9.62%	-22.76%	1,205.82%	-108.19%	-10.74%
NOPAT Q/Q Growth	49.17%	-17.34%	-9.62%	-8.20%	386.93%	-144.30%	-3.74%	-20.13%	765.28%	-111.54%	3.00%
Net Income Q/Q Growth	48.33%	-15.33%	-17.51%	-9.94%	236.87%	-190.85%	-2.91%	-11.35%	179.19%	-78.37%	-1.59%
EPS Q/Q Growth	46.51%	-14.00%	-17.70%	-9.67%	245.41%	-187.68%	-0.47%	-11.30%	146.39%	-75.13%	0.78%
Operating Cash Flow Q/Q Growth	-97.62%	180.27%	-50.58%	1,982.89%	-105.14%	110.38%	-21.60%	189.93%	-81.46%	74.85%	-34.71%
Free Cash Flow Firm Q/Q Growth	23.48%	53.23%	94.75%	-2,167.58%	35.64%	-132.82%	-82.32%	224.90%	-583.76%	414.37%	-12.72%
Invested Capital Q/Q Growth	3.73%	-3.37%	4.68%	-1.10%	3.79%	-0.51%	0.00%	-100.00%	3.82%	-21.85%	2.18%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	28.34%	26.92%	27.56%	28.76%	28.25%	27.08%	27.85%	27.76%	27.98%	29.77%	30.91%
EBITDA Margin	16.16%	8.01%	14.26%	16.01%	17.00%	-2.86%	15.14%	14.40%	16.64%	-1.28%	18.55%
Operating Margin	9.75%	6.50%	7.74%	9.15%	10.11%	-4.05%	8.25%	8.78%	10.86%	-2.49%	13.05%
EBIT Margin	9.72%	7.00%	7.87%	9.76%	10.74%	-3.45%	8.94%	8.22%	10.63%	-1.34%	12.43%
Profit (Net Income) Margin	6.37%	4.31%	5.17%	6.38%	7.19%	-5.50%	6.01%	6.23%	7.02%	3.51%	12.32%
Tax Burden Percent	77.40%	78.13%	80.53%	76.80%	76.77%	113.39%	76.92%	92.24%	78.33%	-97.57%	111.95%
Interest Burden Percent	84.68%	78.92%	81.50%	85.17%	87.14%	140.63%	87.31%	82.20%	84.33%	268.15%	88.52%
Effective Tax Rate	22.60%	21.87%	19.47%	23.20%	23.23%	0.00%	23.08%	24.29%	23.47%	0.00%	12.11%
Return on Invested Capital (ROIC)	7.54%	5.20%	6.12%	13.73%	7.62%	-2.85%	5.22%	0.00%	15.07%	-1.60%	8.57%
ROIC Less NNEP Spread (ROIC-NNEP)	6.76%	4.66%	5.41%	12.86%	7.18%	-5.48%	5.00%	0.00%	12.73%	2.58%	9.17%
Return on Net Nonoperating Assets (RNNOA)	4.18%	2.76%	3.33%	7.68%	3.57%	-1.88%	2.65%	0.00%	4.85%	0.69%	3.64%
Return on Equity (ROE)	11.73%	7.96%	9.44%	21.41%	11.19%	-4.73%	7.87%	0.00%	19.92%	-0.91%	12.21%
Cash Return on Invested Capital (CROIC)	2.76%	2.90%	-2.66%	-192.00%	-2.53%	-2.40%	22.33%	0.00%	-185.28%	28.29%	3.45%
Operating Return on Assets (OROA)	7.50%	5.18%	5.64%	7.29%	7.72%	-2.27%	5.51%	0.00%	6.60%	-0.79%	6.58%
Return on Assets (ROA)	4.92%	3.20%	3.70%	4.77%	5.16%	-3.63%	3.70%	0.00%	4.36%	2.06%	6.52%
Return on Common Equity (ROCE)	11.72%	7.95%	9.44%	21.41%	11.19%	-4.73%	7.87%	0.00%	19.92%	-0.91%	12.21%
Return on Equity Simple (ROE_SIMPLE)	8.81%	0.00%	5.35%	5.63%	5.46%	0.00%	8.41%	0.00%	11.40%	0.00%	17.42%
Net Operating Profit after Tax (NOPAT)	252	169	205	226	247	-86	194	202	252	-38	329
NOPAT Margin	7.54%	5.08%	6.24%	7.03%	7.76%	-2.83%	6.35%	6.65%	8.31%	-1.74%	11.47%
Net Nonoperating Expense Percent (NNEP)	0.78%	0.54%	0.71%	0.87%	0.44%	2.63%	0.22%	0.00%	2.34%	-4.18%	-0.60%
Return On Investment Capital (ROIC_SIMPLE)	1.81%	1.17%	1.37%	1.73%	1.89%	-0.66%	1.46%	-	1.79%	-0.25%	2.13%
Cost of Revenue to Revenue	71.66%	73.08%	72.44%	71.24%	71.75%	72.92%	72.15%	72.24%	72.02%	70.23%	69.09%
SG&A Expenses to Revenue	16.32%	17.88%	17.32%	17.32%	16.00%	17.57%	17.19%	16.67%	15.05%	19.01%	15.81%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	18.59%	20.42%	19.81%	19.61%	18.13%	31.13%	19.59%	18.98%	17.13%	32.26%	17.87%
Earnings before Interest and Taxes (EBIT)	325	233	258	314	341	-105	273	249	323	-29	356
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	540	267	468	516	540	-87	463	437	506	-28	532
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.48	2.51	2.41	2.23	2.40	2.52	2.23	0.00	2.28	2.04	1.81
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	24.26	0.00
Price to Revenue (P/Rev)	1.56	1.56	1.55	1.43	1.55	1.63	1.55	1.90	1.82	1.74	1.70
Price to Earnings (P/E)	28.18	27.13	45.15	39.71	44.08	47.52	26.57	25.39	20.04	16.11	10.41
Dividend Yield	1.24%	0.94%	0.65%	0.36%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.55%	3.69%	2.21%	2.52%	2.27%	2.10%	3.76%	3.94%	4.99%	6.21%	9.60%
Enterprise Value to Invested Capital (EV/IC)	1.92	1.94	1.86	1.77	1.86	1.96	1.77	0.00	1.93	2.19	1.55
Enterprise Value to Revenue (EV/Rev)	1.95	1.93	1.96	1.81	1.96	2.01	1.97	0.00	2.13	2.15	2.15
Enterprise Value to EBITDA (EV/EBITDA)	14.36	14.03	17.32	15.81	17.79	18.54	16.13	0.00	15.01	13.16	9.29
Enterprise Value to EBIT (EV/EBIT)	22.74	21.90	30.74	27.46	31.68	32.99	27.21	0.00	22.29	18.20	12.07
Enterprise Value to NOPAT (EV/NOPAT)	30.17	29.69	47.92	44.23	49.79	50.39	34.76	0.00	26.21	21.94	14.40
Enterprise Value to Operating Cash Flow (EV/OCF)	15.73	15.84	17.92	16.33	20.45	18.41	15.85	0.00	13.59	13.07	11.57
Enterprise Value to Free Cash Flow (EV/FCFF)	70.65	68.13	0.00	0.00	0.00	0.00	7.24	0.00	0.00	6.99	46.54
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.68	0.79	0.83	0.63	0.64	0.65	0.69	0.00	0.61	0.53	0.53
Long-Term Debt to Equity	0.68	0.67	0.66	0.38	0.38	0.52	0.56	0.00	0.57	0.50	0.53
Financial Leverage	0.62	0.59	0.62	0.60	0.50	0.34	0.53	0.00	0.38	0.27	0.40
Leverage Ratio	2.10	2.20	2.21	2.09	2.05	2.05	2.04	0.00	2.02	1.99	1.97
Compound Leverage Factor	1.78	1.74	1.80	1.78	1.78	2.88	1.78	0.00	1.70	5.33	1.75
Debt to Total Capital	40.38%	44.26%	45.25%	38.76%	39.00%	39.41%	40.77%	0.00%	37.82%	34.59%	34.58%
Short-Term Debt to Total Capital	0.00%	6.91%	9.38%	15.45%	15.65%	7.68%	7.46%	0.00%	2.13%	1.95%	0.00%
Long-Term Debt to Total Capital	40.37%	37.35%	35.87%	23.31%	23.36%	31.74%	33.31%	0.00%	35.69%	32.64%	34.58%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.10%	0.10%	0.00%	0.00%	0.00%	0.12%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	59.52%	55.64%	54.75%	61.24%	61.00%	60.47%	59.23%	0.00%	62.18%	65.41%	65.42%
Debt to EBITDA	3.15	3.58	4.70	3.54	3.76	3.89	3.93	0.00	3.43	2.75	2.14
Net Debt to EBITDA	2.85	2.72	3.63	3.34	3.68	3.47	3.38	0.00	2.15	2.55	1.95
Long-Term Debt to EBITDA	3.15	3.02	3.72	2.13	2.25	3.14	3.21	0.00	3.23	2.60	2.14
Debt to NOPAT	6.61	7.57	13.00	9.90	10.53	10.58	8.48	0.00	5.99	4.58	3.32
Net Debt to NOPAT	5.98	5.76	10.05	9.35	10.29	9.42	7.28	0.00	3.75	4.25	3.02
Long-Term Debt to NOPAT	6.61	6.39	10.31	5.96	6.31	8.52	6.93	0.00	5.65	4.33	3.32
Altman Z-Score	2.93	2.66	2.58	2.69	2.80	2.75	2.64	0.00	2.93	2.64	2.61
Noncontrolling Interest Sharing Ratio	0.09%	0.19%	0.00%	0.00%	0.00%	0.09%	0.00%	0.00%	0.00%	0.10%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.84	1.44	1.44	0.88	0.88	1.17	1.36	0.00	2.35	1.50	1.73
Quick Ratio	1.28	1.09	1.10	0.62	0.58	0.82	0.96	0.00	1.82	0.75	1.35
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-236	-308	-659	-12,564	-554	-861	2,623	14,836	-11,879	2,455	-781
Operating Cash Flow to CapEx	14.74%	702.08%	240.29%	438.02%	-22.29%	347.27%	262.88%	340.50%	155.19%	660.87%	452.00%
Free Cash Flow to Firm to Interest Expense	-4.21	-4.86	-13.08	-263.94	-11.81	-17.64	52.14	297.91	-234.29	50.11	-16.87
Operating Cash Flow to Interest Expense	0.33	12.26	5.50	11.79	-0.64	11.88	5.48	7.06	2.39	13.34	8.07
Operating Cash Flow Less CapEx to Interest Expense	-1.91	10.51	3.21	9.10	-3.49	8.46	3.39	4.98	0.85	11.32	6.29
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.77	0.74	0.72	0.75	0.72	0.66	0.62	0.00	0.62	0.59	0.53
Accounts Receivable Turnover	5.88	6.20	5.93	5.56	5.79	5.94	4.48	0.00	5.39	4.77	3.56
Inventory Turnover	19.73	19.39	19.41	20.35	18.46	18.61	17.47	0.00	15.74	18.70	15.84
Fixed Asset Turnover	4.40	4.37	4.33	4.26	4.35	4.26	3.96	0.00	3.98	4.23	3.86
Accounts Payable Turnover	13.45	11.02	13.56	11.82	12.62	10.47	11.14	0.00	10.76	11.07	9.70
Days Sales Outstanding (DSO)	62.03	58.86	61.58	65.66	63.01	61.47	81.50	0.00	67.76	76.54	102.40
Days Inventory Outstanding (DIO)	18.50	18.82	18.81	17.93	19.77	19.61	20.90	0.00	23.20	19.51	23.05
Days Payable Outstanding (DPO)	27.15	33.12	26.92	30.88	28.92	34.85	32.76	0.00	33.91	32.98	37.65
Cash Conversion Cycle (CCC)	53.38	44.56	53.47	52.72	53.85	46.23	69.64	0.00	57.05	63.08	87.80
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	13,420	12,937	13,388	12,790	12,932	12,460	12,524	0.00	12,131	11,685	14,953
Invested Capital Turnover	1.00	1.02	0.98	1.95	0.98	1.01	0.82	0.00	1.81	0.92	0.75
Increase / (Decrease) in Invested Capital	488	477	864	12,790	801	775	-2,429	-14,635	12,131	-2,493	1,110
Enterprise Value (EV)	25,710	25,122	24,880	22,634	24,063	24,448	22,221	0.00	23,395	25,555	23,143
Market Capitalization	20,597	20,237	19,663	17,850	19,091	19,863	17,570	21,090	20,049	20,602	18,282
Book Value per Share	$99.25	$96.27	$97.31	$94.98	$94.43	$92.76	$88.86	$0.00	$99.27	$113.96	$111.64
Tangible Book Value per Share	($19.13)	($21.60)	($22.07)	($18.35)	($19.61)	($18.96)	($19.58)	$0.00	($6.23)	$9.59	($21.39)
Total Capital	13,957	14,472	14,922	13,073	13,049	13,024	13,292	0.00	14,129	15,437	15,427
Total Debt	5,636	6,406	6,752	5,067	5,089	5,133	5,419	0.00	5,344	5,340	5,334
Total Long-Term Debt	5,635	5,406	5,352	3,047	3,048	4,133	4,428	0.00	5,042	5,039	5,334
Net Debt	5,098	4,871	5,218	4,784	4,972	4,569	4,651	0.00	3,346	4,954	4,861
Capital Expenditures (CapEx)	126	111	115	128	134	167	105	103	78	99	83
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,356	958	1,381	1,261	1,457	1,003	1,317	0.00	1,308	1,527	1,440
Debt-free Net Working Capital (DFNWC)	1,726	2,477	2,898	1,526	1,557	1,540	2,044	0.00	3,239	1,848	1,850
Net Working Capital (NWC)	1,725	1,476	1,498	-493	-485	540	1,053	0.00	2,938	1,547	1,850
Net Nonoperating Expense (NNE)	39	26	35	21	18	81	10	13	39	-114	-24
Net Nonoperating Obligations (NNO)	5,098	4,871	5,218	4,784	4,972	4,569	4,651	0.00	3,346	1,588	4,861
Total Depreciation and Amortization (D&A)	215	34	210	201	199	18	189	188	183	1.40	176
Debt-free, Cash-free Net Working Capital to Revenue	10.29%	7.36%	10.86%	10.10%	11.85%	8.25%	11.65%	0.00%	11.89%	12.87%	13.38%
Debt-free Net Working Capital to Revenue	13.09%	19.04%	22.79%	12.22%	12.65%	12.66%	18.09%	0.00%	29.44%	15.58%	17.19%
Net Working Capital to Revenue	13.09%	11.35%	11.78%	-3.95%	-3.94%	4.44%	9.32%	0.00%	26.70%	13.04%	17.19%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.54	$1.72	$2.02	$2.44	$2.71	($1.86)	$2.12	$0.00	$0.00	$0.98	$3.91
Adjusted Weighted Average Basic Shares Outstanding	83.70M	83.70M	83.64M	83.96M	84.29M	84.10M	84.90M	0.00	0.00	88.50M	88.60M
Adjusted Diluted Earnings per Share	$2.52	$1.72	$2.00	$2.43	$2.69	($1.85)	$2.11	$0.00	$0.00	$0.97	$3.90
Adjusted Weighted Average Diluted Shares Outstanding	83.70M	83.70M	83.64M	83.96M	84.29M	84.10M	84.90M	0.00	0.00	88.50M	88.60M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	83.70M	83.70M	83.64M	83.96M	84.29M	84.10M	84.90M	0.00	0.00	88.50M	88.60M
Normalized Net Operating Profit after Tax (NOPAT)	257	180	219	235	252	161	208	216	260	144	338
Normalized NOPAT Margin	7.69%	5.41%	6.68%	7.31%	7.95%	5.29%	6.79%	7.11%	8.55%	6.64%	11.77%
Pre Tax Income Margin	8.23%	5.52%	6.42%	8.31%	9.36%	-4.85%	7.81%	6.76%	8.96%	-3.60%	11.01%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	5.80	3.67	5.13	6.60	7.28	-2.14	5.44	5.01	6.37	-0.60	7.70
NOPAT to Interest Expense	4.51	2.67	4.06	4.76	5.26	-1.76	3.86	4.05	4.98	-0.77	7.10
EBIT Less CapEx to Interest Expense	3.56	1.93	2.84	3.91	4.43	-5.56	3.35	2.94	4.83	-2.61	5.91
NOPAT Less CapEx to Interest Expense	2.26	0.92	1.77	2.07	2.41	-5.18	1.77	1.98	3.44	-2.79	5.31
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	33.15%	32.54%	55.90%	54.91%	57.97%	60.59%	38.72%	30.95%	25.91%	15.24%	0.00%
Augmented Payout Ratio	33.15%	66.02%	93.91%	298.98%	57.97%	299.14%	236.34%	115.08%	25.91%	101.14%	102.40%

Frequently Asked Questions About Laboratory Co. of America's Financials

When does Laboratory Co. of America's fiscal year end?

According to the most recent income statement we have on file, Laboratory Co. of America's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Laboratory Co. of America's net income changed over the last 9 years?

Laboratory Co. of America's net income appears to be on an upward trend, with a most recent value of $747.10 million in 2024, rising from $438.70 million in 2015. The previous period was $419.20 million in 2023. See Laboratory Co. of America's forecast for analyst expectations on what’s next for the company.

What is Laboratory Co. of America's operating income?

Laboratory Co. of America's total operating income in 2024 was $1.09 billion, based on the following breakdown:

Total Gross Profit: $3.62 billion
Total Operating Expenses: $2.54 billion

How has Laboratory Co. of America revenue changed over the last 9 years?

Over the last 9 years, Laboratory Co. of America's total revenue changed from $8.68 billion in 2015 to $13.01 billion in 2024, a change of 49.9%.

How much debt does Laboratory Co. of America have?

Laboratory Co. of America's total liabilities were at $10.31 billion at the end of 2024, a 16.7% increase from 2023, and a 12.8% increase since 2015.

How much cash does Laboratory Co. of America have?

In the past 9 years, Laboratory Co. of America's cash and equivalents has ranged from $316.60 million in 2017 to $1.52 billion in 2024, and is currently $1.52 billion as of their latest financial filing in 2024.

How has Laboratory Co. of America's book value per share changed over the last 9 years?

Over the last 9 years, Laboratory Co. of America's book value per share changed from 49.01 in 2015 to 96.27 in 2024, a change of 96.4%.

Related Companies

This page (NYSE:LH) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Laboratory Co. of America (LH) Financials

Frequently Asked Questions About Laboratory Co. of America's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Laboratory Co. of America (LH) Financials

Annual Income Statements for Laboratory Co. of America

Quarterly Income Statements for Laboratory Co. of America

Annual Cash Flow Statements for Laboratory Co. of America

Quarterly Cash Flow Statements for Laboratory Co. of America

Annual Balance Sheets for Laboratory Co. of America

Quarterly Balance Sheets for Laboratory Co. of America

Annual Metrics And Ratios for Laboratory Co. of America

Quarterly Metrics And Ratios for Laboratory Co. of America

Frequently Asked Questions About Laboratory Co. of America's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools